This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.
Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. ”, our first instinct is to remain patients that CBD is CBD.
If all goes according to plan, patients will receive Sativex and the temozolomide chemotherapy drug, temozolomide on its own, or a placebo. In other positive news on this front, earlier this year the DEA announced that additional US companies would be allowed to supply scientists with cannabis for scientific research.
We want to study what our patients are using,” said University of Colorado Assistant Professor Emily Lindley, who is investigating marijuana with high THC as an alternative to opioids for chronic back pain. Court of Appeals for the District of Columbia to order the DEA to process the applications. “We Others are focused on THC. “We
We want to study what our patients are using,” said University of Colorado Assistant Professor Emily Lindley, who is investigating marijuana with high THC as an alternative to opioids for chronic back pain. Court of Appeals for the District of Columbia to order the DEA to process the applications. “We Others are focused on THC. “We
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].
Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.
We’ve had a cap on that really since 2010 and one way or another, we’ve codified that now to a number of 30. Certain communities have experienced those impacts very differently so patients have experienced impacts differently. JOE: We have a cap of, on our current dispensaries, we have 30 dispensaries. It’s every square inch of it.
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC.
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 3, 2010 , 124 Stat. 3, 2010 , 124 Stat. 109–248, title II , § ? 201, July 27, 2006 , 120 Stat.
A patient or a leisure seeker should be mindful of the cannabis laws, otherwise your trip to paradise might end up in a nightmare. Remember that he made a similar comment in May 2017 when signing that fiscal year’s appropriations bill into law, and yet no raids against state-legal medical marijuana patients or providers followed.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content